Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes

Epigenetics

Volumn 9, Issue 8, 2014, Pages 1108-1119

  Qu, Ying ^a   Lennartsson, Andreas ^a   Gaidzik, Verena I ^b   Deneberg, Stefan ^a,c   Karimi, Mohsen ^a   Bengtzén, Sofia ^a   Höglund, Martin ^d   Bullinger, Lars ^b   Döhner, Konstanze ^b   Lehmann, Sören ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; DNA methylation; DNMT3A; Homeobox gene family; Non CGI region

Indexed keywords

DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTOME; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; BONE MARROW CELL; COHORT ANALYSIS; CPG ISLAND; DNA METHYLATION; FEMALE; GENETICS; HEMATOPOIESIS; HOMEOBOX; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; BONE MARROW CELLS; COHORT STUDIES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; GENES, HOMEOBOX; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; TRANSCRIPTOME; WT1 PROTEINS;

EID: 84905667923     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.29315     Document Type: Article

References (49)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-51; PMID:19357394; http://dx.doi. org/10.1182/blood-2009-03-209262
2. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, et al.; ALFA Group. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100:2717-23; PMID:12351377; http://dx.doi.org/10.1182/blood-2002-03-0990
3. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106:3733-9; PMID:16076867; http://dx.doi.org/10.1182/ blood-2005-06-2248
4. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, et al.; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-18; PMID:18450602; http://dx.doi.org/10.1056/ NEJMoa074306
5. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comblike 1 (ASXL1) mutations. Blood 2010; 116:4086-94; PMID:20693432; http://dx.doi.org/10.1182/ blood-2010-05-283291
6. Patel JPGM, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366:1079-89; PMID:22417203; http://dx.doi.org/10.1056/NEJMoa1112304
7. Bock C, Beerman I, Lien WH, Smith ZD, Gu H, Boyle P, Gnirke A, Fuchs E, Rossi DJ, Meissner A. DNA methylation dynamics during in vivo differentiation of blood and skin stem cells. Mol Cell 2012; 47:633-47; PMID:22841485; http://dx.doi. org/10.1016/j.molcel.2012.06.019
8. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P, Lee H, Aryee MJ, Irizarry RA, Kim K, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010; 467:338-42; PMID:20720541; http://dx.doi. org/10.1038/nature09367
9. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17:13-27; PMID:20060365; http://dx.doi.org/10.1016/j. ccr.2009.11.020
10. Deneberg S, Grövdal M, Karimi M, Jansson M, Nahi H, Corbacioglu A, Gaidzik V, Döhner K, Paul C, Ekström TJ, et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia 2010; 24:932-41; PMID:20237504; http://dx.doi.org/10.1038/ leu.2010.41
11. Yalcin A, Kreutz C, Pfeifer D, Abdelkarim M, Klaus G, Timmer J, Lübbert M, Hackanson B. MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cells. Leuk Res 2013; 37:102-11; PMID:23062266; http://dx.doi.org/10.1016/j.leukres.2012.09.014
12. Bullinger L, Ehrich M, Döhner K, Schlenk RF, Döhner H, Nelson MR, van den Boom D. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010; 115:636-42; PMID:19903898; http://dx.doi.org/10.1182/ blood-2009-03-211003
13. Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, Karimi M, Bengtzén S, Nahi H, Uggla B, et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 2011; 118:5573-82; PMID:21960591; http:// dx.doi.org/10.1182/blood-2011-01-332353
14. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86; PMID:19151715; http://dx.doi. org/10.1038/ng.298
15. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99:247-57; PMID:10555141; http://dx.doi. org/10.1016/S0092-8674(00)81656-6
16. Tadokoro Y, Ema H, Okano M, Li E, Nakauchi H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 2007; 204:715-22; PMID:17420264; http://dx.doi.org/10.1084/ jem.20060750
17. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012; 44:23-31; PMID:22138693; http://dx.doi.org/10.1038/ng.1009
18. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424-33; PMID:21067377; http://dx.doi.org/10.1056/NEJMoa1005143
19. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43:309-15; PMID:21399634; http:// dx.doi.org/10.1038/ng.788
20. Hájková H, Marková J, Haškovec C, Sárová I, Fuchs O, Kostečka A, Cetkovský P, Michalová K, Schwarz J. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. Leuk Res 2012; 36:1128-33; PMID:22749068; http://dx.doi. org/10.1016/j.leukres.2012.05.012
21. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the infinium methylation 450k technology. Epigenomics 2011; 3:771-84; PMID:22126295; http://dx.doi.org/10.2217/ epi.11.105
22. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483:474-8; PMID:22343901; http://dx.doi.org/10.1038/nature10860
23. Holz-Schietinger C, Matje DM, Reich NO. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem 2012; 287:30941-51; PMID:22722925; http://dx.doi.org/10.1074/jbc. M112.366625
24. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013; 122:4086-9; PMID:24167195; http:// dx.doi.org/10.1182/blood-2013-02-483487
25. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 2013; 27:1000-8; PMID:23212154; http://dx.doi.org/10.1038/ leu.2012.356
26. Network TCG A R; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368:2059-74; PMID:23634996; http://dx.doi. org/10.1056/NEJMoa1301689
27. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, Gu ZH, Wang YY, Chen B, Jiang CL, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118:5593-603; PMID:21881046; http:// dx.doi.org/10.1182/blood-2011-03-343988
28. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, Ponjavic J, Semple CA, Taylor MS, Engström PG, Frith MC, et al. Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet 2006; 38:626-35; PMID:16645617; http://dx.doi.org/10.1038/ng1789
29. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006; 76:23-32; PMID:16343268; http://dx.doi. org/10.1111/j.1600-0609.2005.00559.x
30. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 2010; 115:3098-108; PMID:20190193; http://dx.doi.org/10.1182/blood-2009-07-233858
31. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008; 9:465-76; PMID:18463664; http://dx.doi. org/10.1038/nrg2341
32. Goelz BV. Hamilton SR, AP Feinberg, Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985; 228:4
33. Cahill N, Bergh AC, Kanduri M, Göransson-Kultima H, Mansouri L, Isaksson A, Ryan F, Smedby KE, Juliusson G, Sundström C, et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2013; 27:150-8; PMID:22922567; http:// dx.doi.org/10.1038/leu.2012.245
34. Rönnerblad M, Andersson R, Olofsson T, Douagi I, Karimi M, Lehmann S, Hoof I, de Hoon M, Itoh M, Nagao-Sato S, et al.; FANTOM consortium. Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation. Blood 2014; 123:e79-89; PMID:24671952; http://dx.doi.org/10.1182/ blood-2013-02-482893
35. Lee ST, Xiao Y, Muench MO, Xiao J, Fomin ME, Wiencke JK, Zheng S, Dou X, de Smith A, Chokkalingam A, et al. A global DNA methylation and gene expression analysis of early human B-cell development reveals a demethylation signature and transcription factor network. Nucleic Acids Res 2012; 40:11339-51; PMID:23074194; http://dx.doi. org/10.1093/nar/gks957
36. Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 2012; 8:e1002781; PMID:22737091; http://dx.doi.org/10.1371/journal.pgen.1002781
37. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-67; PMID:21130701; http://dx.doi.org/10.1016/j.ccr.2010.11.015
38. John F, Fuller JM. Yifah Yaron, Mark Sakaguchi, John K. Fraser, and Judith C. Gasson, Characterization of hox gene expression during myelopoiesis: Role of hox a5 in lineage commitment and maturation. Blood 1999; 93:10
39. Daga A, Podesta M, Capra MC, Piaggio G, Frassoni F, Corte G. The retroviral transduction of HOXC4 into human CD34(+) cells induces an in vitro expansion of clonogenic and early progenitors. Exp Hematol 2000; 28:569-74; PMID:10812247; http://dx.doi. org/10.1016/S0301-472X(00)00135-1
40. Jeong M, Sun D, Luo M, Huang Y, Challen GA, Rodriguez B, Zhang X, Chavez L, Wang H, Hannah R, et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet 2014; 46:17-23; PMID:24270360; http://dx.doi.org/10.1038/ ng.2836
41. Vidovic K, Svensson E, Nilsson B, Thuresson B, Olofsson T, Lennartsson A, Gullberg U. Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. Leukemia 2010; 24:992-1000; PMID:20237505; http://dx.doi.org/10.1038/leu.2010.33
42. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005; 104:1924-30; PMID:16134181; http://dx.doi.org/10.1002/cncr.21397
43. Hancock AL, Brown KW, Moorwood K, Moon H, Holmgren C, Mardikar SH, Dallosso AR, Klenova E, Loukinov D, Ohlsson R, et al. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis. Hum Mol Genet 2007; 16:343-54; PMID:17210670; http://dx.doi. org/10.1093/hmg/ddl478
44. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466:253-7; PMID:20613842; http:// dx.doi.org/10.1038/nature09165
45. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28:3636-43; PMID:20567020; http:// dx.doi.org/10.1200/JCO.2010.28.3762
46. Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 2013; 121:4769-77; PMID:23632886; http://dx.doi.org/10.1182/ blood-2012-10-461624
47. FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature 2014; 507:462-70; PMID:24670764; http://dx.doi.org/10.1038/ nature13182
48. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012; 28:882-3; PMID:22257669; http://dx.doi.org/10.1093/bioinformatics/bts034
49. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010; 26:1572-3; PMID:20427518; http://dx.doi.org/10.1093/ bioinformatics/btq170